High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-positive breast cancers, no tailored therapy exists for hormone receptor- and ERBB2-negative (“triple-negative”) mammary carcinomas. Triple-negative tumors account for 15% of all breast cancers and fre...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Rottenberg, Sven, Jaspers, Janneke E., Kersbergen, Ariena, van der Burg, Eline, Nygren, Anders O. H., Zander, Serge A. L., Derksen, Patrick W. B., de Bruin, Michiel, Zevenhoven, John, Lau, Alan, Boulter, Robert, Cranston, Aaron, O'Connor, Mark J., Martin, Niall M. B., Borst, Piet, Jonkers, Jos
Materialtyp: Artigo
Språk:Inglês
Publicerad: National Academy of Sciences 2008
Ämnen:
Biological Sciences
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2579381/
https://ncbi.nlm.nih.gov/pubmed/18971340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0806092105
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk